The UK approval of once-daily oral Wegovy is a significant moment for obesity treatment. For the first time, patients can access semaglutide for chronic weight management without using an injection, widening the range of formulations available and potentially removing a genuine barrier for people with needle anxiety.
Yet the arrival of a tablet should not be mistaken for the arrival of an effortless treatment pathway.
Oral semaglutide may feel familiar, but its clinical use is unusually dependent on careful administration and patient understanding. That dependence stems from the formulation challenge. Enabling a peptide medicine, which would ordinarily be broken down in the gastrointestinal tract, to be absorbed orally is an impressive pharmaceutical achievement.
Check out the rest of the feature here
